Morgan Stanley and Goldman Sachs Upgraded Exelixis Stock Rating and Price Target

Summary

Exelixis shares are trading higher after Morgan Stanley maintained its Overweight rating and raised its price target to $50. Goldman Sachs also initiated coverage with a BUY rating and a price target of $47.benzinga_article

Impact Analysis

So basically, Morgan Stanley and Goldman Sachs are signaling strong confidence in Exelixis’s future, which is intriguing given the mixed financial backdrop. Morgan Stanley’s $50 target and Goldman’s $47 target suggest they see upside potential, likely driven by Exelixis’s promising pipeline, including zanzalintinib, which could fill the revenue gap post-Cabometyx exclusivity loss Tip Ranks. The timing is interesting, as it comes amid a broader market maturity and potential legal challenges MorningStar. The technicals show a mixed picture with a long-term downtrend but short-term strength, suggesting a cautious approach . The market might be underestimating the potential for Exelixis to capture market share in neuroendocrine tumors, which could be a catalyst for further gains Tip Ranks. However, the high short interest indicates some skepticism remains Benzinga. Overall, this feels like a calculated bet on Exelixis’s ability to execute on its growth strategy.